Re: Short Interest continues to drop

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KOO-KOO2

Rank: Treasurer [?]

Points: 10765 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Short Interest continues to drop

in response to

Re: Short Interest continues to drop

fuzzyjr

posted on Nov 29, 2023 11:31AM

"I was hoping for news by Dec 15th - if not hopefully in the first quarter of 2023."

Fuzzy, if the hope is that the financing for RVX (BOM2) is by way of the following;

1) Resverlogix Royalty Preferred Shares, 6-12% ascending royalty on global net sales :

and

2) Zenith ZEN-3694 IP, continued value rights (CVR) potential, 8% royalty.

All of the above (allegedly already in discussion) hinges on the success of the ongoing ZEN-3694 clinical trials in collaboration and in the hands and in full control of BigPharma. What BP will do with any potential successes is the unknown and timing may be a long way off. The question is how long will the wait be in the hopes of these scenarios coming to fruition? There has to be a better way, a much quicker way before things really bust up for RVX.

The lack of funding for RVX (in comparison to the ongoing funding for Zenith) is the part that boggles my mind about how it's managing to remain afloat. Zenith seems to be well on its way with support from BP and the ongoing Exempt Distribution funding.

I still say that an IPO for Zenith (in the hands of an investment banker) and professional guidance from Cencora would be the quickest way to raise the necessary funds to help RVX get BOM2 on its way.